Abbvie pays 49% premium for Abivax acquisition
Pharmaceutical giant Abbvie has announced a takeover offer for Abivax at a 49% premium to closing price.
Published 4sem1 sourceImportantupdated 4j
Lire en français
≈ 20s
The fact
This transaction values the French biotech at a significant premium, reflecting interest in its therapeutic pipeline.
The acquisition illustrates ongoing consolidation in the biotech and pharmaceutical sector.
Click the link to read an article on the topic: